[1] 郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
[2] Wang W, Sun Z, Deng J, et al. Integration and analysis of associated data in surgical treatment of gastric cancer based on multicenter,high volume databases[J]. Chin J Gastrointest Surg, 2016, 19( 2):179-185
[3] Rivera F, Romero C, Jimenez-Fonseca P, et al. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial [J]. Cancer Chemother Pharmacol, 2019, 83(6): 1175-1181.
[4] Bubnovskaya L, Osinsky D. Tumor microenvironment and metabolic factors: contribution to gastric cancer [J]. Exp Oncol, 2020, 42(1): 2-10.
[5] Kim S J, Uehara H, Karashima T, et al. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice[J]. Clin Cancer Res, 2003, 9(3):1200-1210.
[6] Gao M, Liang X J, Zhang Z S, et al. Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features[J]. Asian Pac J Trop Med, 2013, 6(4):260-264.
[7] Maciel T T, Moura I C, Hermine O. The role of mast cells in cancers[J]. F1000Prime Rep,2015,7: 9.
[8] Varricchi G, Galdiero M R, Loffredo S, et al. Are mast cells MASTers in cancer?[J]. Front Immunol, 2017, 8: 424.
[9] Rojas A, Araya P, Gonzalez I, et al. Gastric tumor microenvironment [J]. Adv Exp Med Biol, 2020, 1226:23-35.
[10] Noto C N, Hoft S G, DiPaolo R J. Mast cells as important regulators in autoimmunity and cancer development[J]. Front Cell Dev Biol, 2021, 9: 752350.
[11] Kwa M Q, Herum K M, Brakebusch C. Cancer-associated fibroblasts: how do they contribute to metastasis? [J]. Clin Exp Metastasis, 2019, 36(2):71-86.
[12] Zhu S, Shi J, Zhang S, et al. KLK6 promotes growth, migration, and invasion of gastric cancer cells[J]. J Gastric Cancer, 2018, 18(4):356-367.
[13] Yue Y C, Yang B Y, Lu J, et al. Metabolite secretions of Lactobacillus plantarum YYC-3 may inhibit colon cancer cell metastasis by suppressing the VEGF-MMP2/9 signaling pathway[J]. Microb Cell Fact, 2020, 19(1):213.
[14] Jabońska-Trypuc A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs[J]. J Enzyme Inhib Med Chem, 2016, 31(sup1):177-183.
[15] Wang Z, Yang Y, Cui Y, et al. Tumor-associated macrophages regulate gastric cancer cell invasion and metastasis through TGFβ₂/NF-κB/Kindlin-2 axis[J]. Chin J Cancer Res, 2020, 32(1):72-88.
[16] Byeon S, Hong J Y, Lee J, et al. Use of gefitinib in EGFR-amplified refractory solid tumors: an open-label, single-arm, single-center prospective pilot study[J]. Target Oncol, 2020, 15(2):185-192.
[17] Sanchez-Vega F, Hechtman J F, Castel P, et al. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer[J]. Cancer Discov, 2019, 9(2):199-209.
[18] Kim T Y, Han H S, Lee K W, et al. A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer [J]. Gastric Cancer, 2019, 22(6):1206-1214.
[19] Malka D, Franois E, Penault-Llorca F, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA):a randomised,open-label,three-arm phase II trial[J]. Eur J Cancer, 2019, 115:97-106.
[20] Quintero Aldana G, Salgado M, Candamio S, et al. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial[J]. Clin Transl Oncol, 2020, 22(4): 495-502.
[21] Stahl M, Maderer A, Lordick F, et al. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801) [J]. Eur J Cancer, 2018, 93:119-126.
[22] Oh D Y, Lee K W, Han S W, et al. A first-in-human phase I study of GC1118, a novel anti-epidermal growth factor receptor antibody, in patients with advanced solid tumors[J]. Oncologist, 2019, 24(8):1037-e636.
[23] Kirschbrown W P, Wang B, Nijem I, et al. Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer[J]. Cancer Chemother Pharmacol, 2019, 84(3): 539-550.
[24] Liu T, Qin Y, Li J, et al. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial[J]. Cancer Commun (Lond), 2019, 39(1):38.
[25] Shitara K, Hara H, Yoshikawa T, et al. Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial[J]. Int J Clin Oncol, 2020, 25(2): 301-311.
[26] Catenacci D V T, Kang Y K, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated,HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05):a single-arm, phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8):1066-1076.
[27] Shah M A, Kang Y K, Thuss-Patience P C, et al. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer[J]. Gastric Cancer, 2019, 22(4):803-816.
[28] Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study[J]. Lancet Oncol, 2019, 20(6):827-836.
[29] Shitara K, Bang Y J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J]. N Engl J Med, 2020, 382(25):2419-2430.
[30] Hosoda K, Yamashita K, Ushiku H, et al. Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy[J]. Oncol Lett, 2018,15(2):1853-1860.
[31] Kim S B, Meric-Bernstam F, Kalyan A, et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer[J]. Target Oncol, 2019, 14(5): 591-601.
[32] Macedo F, Ladeira K, Longatto-Filho A, et al. Gastric cancer and angiogenesis: is VEGF a useful biomarker to assess progression and remission? [J]. J Gastric Cancer, 2017, 17:1-10.
[33] Chau I, Penel N, Soriano A O, et al. Ramucirumab in combination with pembrolizumab in treatment-nve advanced gastric or GEJ adenocarcinoma: safety and antitumor activity from the phase 1a/b JVDF trial[J]. Cancers (Basel), 2020, 12(10): 2985.
[34] Bang Y J, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ)[J]. Eur J Cancer, 2020, 137:272-284.
[35] Di Bartolomeo M, Niger M, Morano F, et al. Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial [J]. BMC Cancer, 2019, 19(1):283.
[36] Kang Y, Kang W, Di Bartolomeo M, et al. LBA43 Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens[J]. Ann Oncol, 2019, 30: mdz394.
[37] Zheng Y, Yang X, Yan C, et al. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: a single-arm, open-label, phase II trial[J]. Eur J Cancer, 2020, 137:12-19.
[38] Shah M A, Starodub A, Sharma S, et al. Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study[J]. Clin Cancer Res, 2018, 24(16):3829-3837.
[39] Shah M A, Bodoky G, Starodub A, et al. Phase III study to evaluate efficacy and safety of andecaliximab with mFOLFOX6 as first-Line treatment in patients with advanced gastric or GEJ adenocarcinoma (GAMMA-1)[J]. J Clin Oncol, 2021, 39(9):990-1000.
[40] Principe D R, Doll J A, Bauer J, et al. TGF-b: duality offunction between tumor prevention and carcinogenesis[J]. J Natl Cancer Inst, 2014, 106: djt369.
[41] Akhurst R J, Hata A. Targeting the TGFb signalling pathway in disease[J]. Nat Rev Drug Discov, 2012, 11:790-811.
[42] Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824,a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-b[J]. Sci Transl Med, 2018, 10:eaan5488.
[43] Kang Y K, Bang Y J, Kondo S, et al. Safety and tolerability of bintrafusp Alfa, a bifunctional fusion protein targeting TGFβ and PD-L1, in Asian patients with pretreated recurrent or refractory gastric cancer [J]. Clin Cancer Res, 2020, 26(13):3202-3210.
[44] Wang J, Wu D X, Meng L, et al. Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer:study protocol for a single-armed and single-centred clinical trial[J]. BMJ Open, 2020, 10(6):034685.
[45] Mukherjee S, Fountzilas C, Boland P M, et al. Phase I study of irinotecan/5-fluorouracil/leucovorin (FOLFIRI) with sunitinib for advanced gastric or gastroesophageal junction adenocarcinoma[J]. Target Oncol, 2020, 15(1): 85-92.
[46] Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer(LUME-Lung 1): a phase 3, double-blind, randomised controlled trial[J]. Lancet Oncol, 2014, 15: 143-55.
[47] Won E, Basunia A, Chatila W K, et al. Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer[J]. Clin Cancer Res, 2019, 25(13):3811-3817.